ABIVAX Société Anonyme (ABVX) Competitors $7.65 -0.11 (-1.42%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ABVX vs. AMPH, IRON, TARS, CGON, HRMY, GLPG, XNCR, EVO, ARQT, and NRIXShould you be buying ABIVAX Société Anonyme stock or one of its competitors? The main competitors of ABIVAX Société Anonyme include Amphastar Pharmaceuticals (AMPH), Disc Medicine (IRON), Tarsus Pharmaceuticals (TARS), CG Oncology (CGON), Harmony Biosciences (HRMY), Galapagos (GLPG), Xencor (XNCR), Evotec (EVO), Arcutis Biotherapeutics (ARQT), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. ABIVAX Société Anonyme vs. Amphastar Pharmaceuticals Disc Medicine Tarsus Pharmaceuticals CG Oncology Harmony Biosciences Galapagos Xencor Evotec Arcutis Biotherapeutics Nurix Therapeutics Amphastar Pharmaceuticals (NASDAQ:AMPH) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation. Do analysts recommend AMPH or ABVX? Amphastar Pharmaceuticals currently has a consensus price target of $60.33, suggesting a potential upside of 54.15%. ABIVAX Société Anonyme has a consensus price target of $38.67, suggesting a potential upside of 405.45%. Given ABIVAX Société Anonyme's stronger consensus rating and higher possible upside, analysts clearly believe ABIVAX Société Anonyme is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50ABIVAX Société Anonyme 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, AMPH or ABVX? Amphastar Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, ABIVAX Société Anonyme has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Is AMPH or ABVX more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to ABIVAX Société Anonyme's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat ABIVAX Société Anonyme's return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% ABIVAX Société Anonyme N/A N/A N/A Does the MarketBeat Community prefer AMPH or ABVX? Amphastar Pharmaceuticals received 384 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 80.00% of users gave ABIVAX Société Anonyme an outperform vote while only 66.22% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39266.22% Underperform Votes20033.78% ABIVAX Société AnonymeOutperform Votes880.00% Underperform Votes220.00% Which has stronger valuation & earnings, AMPH or ABVX? Amphastar Pharmaceuticals has higher revenue and earnings than ABIVAX Société Anonyme. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$723.55M2.60$137.54M$3.0013.05ABIVAX Société AnonymeN/AN/A-$159.90MN/AN/A Does the media refer more to AMPH or ABVX? In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 3 mentions for ABIVAX Société Anonyme. ABIVAX Société Anonyme's average media sentiment score of 1.08 beat Amphastar Pharmaceuticals' score of 0.98 indicating that ABIVAX Société Anonyme is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ABIVAX Société Anonyme 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in AMPH or ABVX? 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of ABIVAX Société Anonyme shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAmphastar Pharmaceuticals beats ABIVAX Société Anonyme on 10 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get ABIVAX Société Anonyme News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVX vs. The Competition Export to ExcelMetricABIVAX Société AnonymePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$484.61M$6.57B$5.13B$9.08BDividend YieldN/A2.99%4.91%4.22%P/E RatioN/A10.5591.4117.18Price / SalesN/A195.351,113.72116.79Price / CashN/A57.1642.7137.86Price / Book2.275.104.794.78Net Income-$159.90M$151.51M$120.07M$225.60M7 Day Performance7.59%-2.14%-1.92%-1.23%1 Month Performance-11.56%-3.13%11.46%3.36%1 Year Performance-29.23%11.53%30.49%16.59% ABIVAX Société Anonyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVXABIVAX Société Anonyme2.1867 of 5 stars$7.65-1.4%$38.67+405.4%-27.6%$484.61MN/A0.0061Positive NewsGap UpHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.8572 of 5 stars$41.13-2.6%$60.33+46.7%-33.1%$1.98B$644.40M14.081,761Positive NewsIRONDisc Medicine3.3068 of 5 stars$66.27+2.1%$87.50+32.0%+13.2%$1.97BN/A-16.3078Insider TradeTARSTarsus Pharmaceuticals0.3253 of 5 stars$51.48-1.9%$54.20+5.3%+164.4%$1.97B$17.45M-13.7850Positive NewsCGONCG Oncology2.1538 of 5 stars$28.54-0.8%$63.88+123.8%N/A$1.93B$684,000.000.0061Insider TradeHRMYHarmony Biosciences4.7837 of 5 stars$32.87+1.5%$47.00+43.0%+7.0%$1.87B$681.88M15.35200Analyst ForecastAnalyst RevisionGLPGGalapagos0.6161 of 5 stars$27.03+0.8%$30.75+13.8%-31.4%$1.78B$260.09M0.001,123XNCRXencor4.3163 of 5 stars$25.05+4.2%$36.56+45.9%+18.4%$1.75B$168.34M-7.51280EVOEvotec2.3873 of 5 stars$4.70+4.7%$5.93+26.2%-60.5%$1.67B$777.05M0.005,061Positive NewsARQTArcutis Biotherapeutics0.8607 of 5 stars$13.31+4.9%$15.50+16.5%+478.8%$1.56B$138.71M-7.58150Options VolumeNRIXNurix Therapeutics2.5081 of 5 stars$21.09+4.0%$30.35+43.9%+101.7%$1.49B$56.42M-6.97300News Coverage Related Companies and Tools Related Companies AMPH Competitors IRON Competitors TARS Competitors CGON Competitors HRMY Competitors GLPG Competitors XNCR Competitors EVO Competitors ARQT Competitors NRIX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABVX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABIVAX Société Anonyme Please log in to your account or sign up in order to add this asset to your watchlist. Share ABIVAX Société Anonyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
